Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Conference News AHA 2024

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Michael O'Riordan

November 21, 2024

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

Presentation AHA 2024

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Presenter: Kausik K. Ray

November 17, 2024

News Conference News AHA 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Michael O'Riordan

November 06, 2022

News Conference News AHA 2021

ApoB Gains Ground as Best Lipid Predictor of MI Risk

Michael O'Riordan

November 22, 2021

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Shelley Wood

November 08, 2021

News Conference News AHA 2020

OMEMI: Omega-3 Fatty Acids No Help in Elderly MI Patients

Todd Neale

November 15, 2020

News Conference News AHA 2020

Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol

Michael O'Riordan

November 12, 2020

News Conference News AHA 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Yael L. Maxwell

November 21, 2019

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Shelley Wood

November 05, 2018

News Conference News AHA 2016

类药物相关的肌肉疼痛？GAUSS-3 分析称可能基因决定的

Michael O'Riordan

November 22, 2016

News Conference News AHA 2016

¿Dolor Muscular Secundario a las Estatinas? Según el Análisis GAUSS-3 Podría ser Genético

Michael O'Riordan

November 22, 2016

News Conference News AHA 2016

Statin-Associated Muscle Pain? It May Be Your Genes, Says GAUSS-3 Analysis

Michael O'Riordan

November 22, 2016

News Conference News AHA 2015

Knowing Genetic Risk for MI Motivates Patients, Physicians to Get Cholesterol Levels Lower

Yael L. Maxwell

November 08, 2015

Advertisement

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

ApoB Gains Ground as Best Lipid Predictor of MI Risk

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

OMEMI: Omega-3 Fatty Acids No Help in Elderly MI Patients

Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

类药物相关的肌肉疼痛？GAUSS-3 分析称可能基因决定的

¿Dolor Muscular Secundario a las Estatinas? Según el Análisis GAUSS-3 Podría ser Genético

Statin-Associated Muscle Pain? It May Be Your Genes, Says GAUSS-3 Analysis

Knowing Genetic Risk for MI Motivates Patients, Physicians to Get Cholesterol Levels Lower

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content